Claudia Asperti Selected Research

mouse CNGRC fusion protein tumor Necrosis Factor-alpha

10/2015

The tumor vessel targeting agent NGR-TNF controls the different stages of the tumorigenic process in transgenic mice by distinct mechanisms.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Claudia Asperti Research Topics

Disease

5	Neoplasms (Cancer) 01/2021 - 01/2011
1	Carcinogenesis 01/2020
1	Multiple Myeloma 01/2020
1	Neoplasm Metastasis (Metastasis) 01/2020
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020

Drug/Important Bio-Agent (IBA)

2	Chimeric Antigen ReceptorsIBA 01/2021 - 01/2020
2	AntigensIBA 01/2021 - 01/2020
2	Protein Isoforms (Isoforms)IBA 01/2020 - 09/2019
1	CD44v6 antigenIBA 01/2020
1	Peptides (Polypeptides)IBA 09/2019
1	NGR peptideIBA 09/2019
1	Pharmaceutical PreparationsIBA 09/2019
1	human CNGRC fusion protein tumor necrosis factor-alphaIBA 09/2019
1	mouse CNGRC fusion protein tumor Necrosis Factor-alphaIBA 10/2015
1	Proteins (Proteins, Gene)FDA Link 01/2011
1	IntegrinsIBA 01/2011

Therapy/Procedure

1	Therapeutics 01/2020
1	Transplantation 10/2015